Laser therapy offers hope for cancer survivors with menopause symptoms
NCT ID NCT07420647
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a non-hormonal laser treatment for genitourinary syndrome of menopause (GSM) in women who have completed cancer treatment. GSM causes symptoms like vaginal dryness and pain, which can affect quality of life. The study will compare the laser therapy to a control group in 65 women, using questionnaires and exams to see if symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Non-ablative vaginal Er:YAG laser therapy
- What this could lead to
- If this works, it could offer a safe, non-hormonal option to ease vaginal dryness and pain for women who have had cancer treatment.
- What could go wrong
- This is a small pilot study with only 65 participants, so results may not apply to everyone. The laser therapy is still experimental and may not work for all women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
65 people
The number who actually took part.
- Started
-
Oct 2024
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Female sex. Postmenopausal women. History of oncological treatment (e.g., gynecological or other malignancies). Presence of genitourinary syndrome of menopause (GSM), including symptoms such as vaginal dryness, dyspareunia, burning, irritation, or urinary symptoms. Completion of primary oncological treatment prior to enrollment. Age ≥ 18 years. Ability to understand the study procedures and provide written informed consent Exclusion Criteria: Current pregnancy or premenopausal status. Active malignant disease requiring ongoing oncological treatment. Acute genital or urinary tract infection at the time of enrollment. Prior participation in another interventional clinical study that could influence study outcomes. Known hypersensitivity or contraindication to study-related interventions. Any medical or psychiatric condition that, in the investigator's opinion, would interfere with study participation or outcome assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Female cancer survivors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two estradiol dosing schedules put brain effects to the test
- Can strength training steady the walk and strengthen the pelvic floor after menopause?
- Can a brazilian diet calm menopause hot flashes?
- Can Omega-3s keep menopausal minds sharp?
- Does hormone therapy for menopause leave a mark on breasts and arteries?
- A phone game takes on menopause brain fog